By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Upsher-Smith Laboratories, Inc. 

14905 23rd Avenue North

Minneapolis  Minnesota  55447  U.S.A.
Phone: 800-328-3344 Fax:


SEARCH JOBS








Company News
Upsher-Smith Laboratories And Sanion Sign Collaboration Agreement For Development Of Novel Therapeutics For Neurological Disorders 1/20/2016 7:36:22 AM
Upsher-Smith Laboratories Release: Seizure Clusters Significantly Impact Quality Of Life For Patients And Their Caregivers, According To A Landmark Survey Conducted By Harris Poll 12/7/2015 12:22:08 PM
Upsher-Smith Laboratories Presents Data Evaluating PK, PD And Tolerability Of Investigational Midazolam Nasal Spray In Healthy Geriatric And Non-Geriatric Adults 12/7/2015 7:55:58 AM
Roche (RHHBY), Upsher-Smith Laboratories Partner Up to Develop Inflammatory Disease Drug 12/1/2015 6:09:35 AM
Upsher-Smith Laboratories To Present New Data On Qudexy XR (topiramate) Extended-Release Capsules And USL261 (Investigational Intranasal Midazolam) 11/23/2015 7:28:48 AM
Upsher-Smith Laboratories Release: Data Published In Epilepsia Shows USL261 (Intranasal Midazolam) Demonstrated A Promising Pharmacokinetic Profile, Including Increased Relative Bioavailability, When Compared With Injectable Midazolam Administered Intranasally 11/9/2015 7:29:40 AM
Upsher-Smith Laboratories Names Rusty Field President 8/24/2015 7:53:59 AM
Upsher-Smith Laboratories Receives FDA Approval For Generic Version Of Namenda (Memantine HCl) Tablets 8/10/2015 8:03:12 AM
Upsher-Smith Laboratories's ANDROXY (Fluoxymesterone Tablets, USP) CIII Now Available 7/27/2015 11:24:47 AM
Upsher-Smith Laboratories Release: FDA Approves Expanded Indication For Qudexy XR (Topiramate) Extended-Release Capsules Within The Pediatric Population 6/1/2015 7:30:06 AM
12345678910...
//-->